Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study

C Senn, B Günther, A W Popp, R Perrelet, D Hans, K Lippuner, C Senn, B Günther, A W Popp, R Perrelet, D Hans, K Lippuner

Abstract

Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug.

Introduction: The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1-34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.

Methods: Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (N = 65) or quarterly intravenous IBN (N = 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared.

Results: Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9 ± 7.4 years, body mass index 23.8 ± 3.8 kg/m(2), BMD L1-L4 0.741 ± 0.100 g/cm(2), and TBS 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively; P < 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (r (2) = 0.04) with no correlation between the changes in BMD and TBS over 24 months.

Conclusions: In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.

References

    1. J Bone Miner Res. 2007 Jun;22(6):841-8
    1. J Clin Endocrinol Metab. 1999 Sep;84(9):3076-81
    1. Curr Osteoporos Rep. 2004 Jun;2(2):47-52
    1. Clin Interv Aging. 2011;6:89-99
    1. J Bone Miner Res. 2007 Aug;22(8):1173-80
    1. Osteoporos Int. 2012 Sep;23(9):2329-33
    1. Arthritis Rheum. 2001 Jul;44(7):1496-503
    1. J Bone Miner Res. 2014 Feb;29(2):399-407
    1. Sao Paulo Med J. 2008 Sep;126(5):279-84
    1. J Endocrinol Invest. 2004 Jan;27(1):99-105
    1. Osteoporos Int. 2013 Mar;24(3):1073-8
    1. Bone. 2013 Nov;57(1):232-6
    1. Osteoporos Int. 2006 Dec;17(12):1726-33
    1. Indian J Orthop. 2011 Jan;45(1):15-22
    1. J Bone Miner Metab. 2004;22(6):530-40
    1. N Engl J Med. 2001 May 10;344(19):1434-41
    1. World Health Organ Tech Rep Ser. 1994;843:1-129
    1. Osteoporos Int. 2012 Aug;23(8):2141-50
    1. Bone. 2008 Apr;42(4):775-87
    1. N Engl J Med. 2007 May 3;356(18):1809-22
    1. Osteoporos Int. 2013 Jan;24(1):77-85
    1. N Engl J Med. 2007 Nov 15;357(20):2028-39
    1. J Bone Miner Res. 2013 Mar;28(3):449-54
    1. J Clin Densitom. 2011 Jul-Sep;14(3):302-12
    1. J Bone Miner Res. 2005 Jul;20(7):1185-94
    1. Osteoporos Int. 2011 Oct;22(10):2709-19
    1. Calcif Tissue Int. 2011 Aug;89(2):130-9
    1. Ortop Traumatol Rehabil. 2007 Jul-Aug;9(4):337-56
    1. J Clin Densitom. 2009 Apr-Jun;12(2):170-6
    1. Eur J Endocrinol. 2012 Jan;166(1):87-97
    1. J Bone Miner Res. 2011 Nov;26(11):2762-9
    1. J Bone Miner Res. 2003 Nov;18(11):1932-41
    1. J Bone Miner Res. 2007 Mar;22(3):465-75
    1. South Med J. 2001 Jun;94(6):569-73
    1. Curr Med Res Opin. 2005 Jul;21(7):1049-56
    1. Bone. 2010 Mar;46(3):660-5
    1. J Clin Densitom. 2014 Jan-Mar;17(1):60-5
    1. Osteoporos Int. 2013 Mar;24(3):991-8
    1. Bone. 2000 Aug;27(2):271-6
    1. Curr Med Res Opin. 2012 Mar;28(3):475-91
    1. J Clin Endocrinol Metab. 2009 Jul;94(7):2495-501
    1. N Engl J Med. 2006 May 25;354(21):2250-61
    1. Am J Manag Care. 2006 May;12(7 Suppl):S181-90
    1. J Clin Endocrinol Metab. 2013 May;98(5):1963-70
    1. J Bone Miner Metab. 2010;28(1):68-76
    1. J Clin Densitom. 2006 Jan-Mar;9(1):15-21
    1. J Bone Miner Res. 2000 Jun;15(6):1006-13

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する